Harrow EV/EBIT HROW

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2020.

Today, Oct 23, 2026: n/m; an operating loss
Last meaningful: 87.1×; Aug 2026
7-year median: 130×
7-year range: 23.4× to 476×
Peer median: 8.5×

Harrow has no meaningful EV/EBIT today: it made an operating loss of $2.7M over the last twelve months.

It was last meaningful in Aug 2026, at 87.1×.

On the days it had one over the last 7 years, its median was 130×, from 23.4× in Aug 2021 to 476× in Aug 2023.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	87.1×	46.4×	98.8×
2025	75.7×	61.0×	317×
2024	155×	145×	159×
2023	162×	140×	476×
2022	233×	37.3×	321×
2021	45.1×	23.4×	270×
2020	144×	73.1×	147×

Against its peers

Companies in Drug Manufacturers - General nearest Harrow's size, closest first, today.

Company	EV/EBIT
HROWHarrow	n/m
AMPHAmphastar Pharmaceuticals	12.2×
OMEROmeros	n/m
ABUSArbutus Biopharma	4.9×
PCRXPacira BioSciences	7.6×
ANABAnaptysbio	n/m
COLLCollegium Pharmaceutical	9.4×
PAHCPhibro Animal Health	11.7×
ANIPANI Pharmaceuticals	10.5×
CRMDCorMedix	2.3×
ZVRAZevra Therapeutics	2.9×
Peer median	8.5×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Harrow

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.